CR20210495A - Compuestos macrocíclicos como agonistas de sting - Google Patents

Compuestos macrocíclicos como agonistas de sting

Info

Publication number
CR20210495A
CR20210495A CR20210495A CR20210495A CR20210495A CR 20210495 A CR20210495 A CR 20210495A CR 20210495 A CR20210495 A CR 20210495A CR 20210495 A CR20210495 A CR 20210495A CR 20210495 A CR20210495 A CR 20210495A
Authority
CR
Costa Rica
Prior art keywords
macrocyclic compounds
sting agonists
compounds
disclosed
macrocyclic
Prior art date
Application number
CR20210495A
Other languages
English (en)
Inventor
Pradeep Rangrao Patil
Venkata P Palle
Moloy Banerjee
Rajender Kumar Kamboj
Navnath Popat Karche
Vaibhav Madhukar Kalhapure
Deepak Sahebrao Walke
Vinod Popatrao Vyavahare
Vidya Ramdas
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CR20210495A publication Critical patent/CR20210495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.
CR20210495A 2019-03-28 2020-03-21 Compuestos macrocíclicos como agonistas de sting CR20210495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921012258 2019-03-28
IN201921046194 2019-11-13
PCT/IB2020/052654 WO2020194160A1 (en) 2019-03-28 2020-03-21 Macrocyclic compounds as sting agonists

Publications (1)

Publication Number Publication Date
CR20210495A true CR20210495A (es) 2021-10-18

Family

ID=70293003

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210495A CR20210495A (es) 2019-03-28 2020-03-21 Compuestos macrocíclicos como agonistas de sting

Country Status (19)

Country Link
US (1) US20220144852A1 (es)
EP (1) EP3946610A1 (es)
JP (1) JP7530380B2 (es)
KR (1) KR20210146370A (es)
CN (1) CN113631228B (es)
AU (1) AU2020245263A1 (es)
BR (1) BR112021018947A2 (es)
CA (1) CA3132508A1 (es)
CL (1) CL2021002480A1 (es)
CO (1) CO2021012559A2 (es)
CR (1) CR20210495A (es)
EC (1) ECSP21071644A (es)
IL (1) IL286526A (es)
MA (1) MA55517A (es)
MX (1) MX2021011686A (es)
PE (1) PE20220169A1 (es)
SG (1) SG11202109191SA (es)
WO (1) WO2020194160A1 (es)
ZA (1) ZA202106629B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220035955A (ko) * 2019-07-22 2022-03-22 루핀 리미티드 Sting 작용제로서의 거대고리 화합물 및 이의 방법 및 용도
BR112022001931A2 (pt) 2019-08-02 2022-06-21 Mersana Therapeutics Inc Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
AU2022208054A1 (en) * 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
US9708324B2 (en) * 2015-02-05 2017-07-18 Merck Patent Gmbh Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancer and other medical disorders
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
AU2017247806B2 (en) 2016-04-07 2019-11-14 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
NZ745957A (en) 2016-04-07 2020-07-31 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
MX2019015468A (es) 2017-06-22 2020-08-03 Curadev Pharma Ltd Moduladores de moleculas pequeñas de sting humana.
US20200172483A1 (en) 2017-06-22 2020-06-04 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
EP3642184A1 (en) * 2017-06-22 2020-04-29 Curadev Pharma Limited Small molecule modulators of human sting
WO2019023635A1 (en) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
MA49773A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b

Also Published As

Publication number Publication date
IL286526A (en) 2021-10-31
CA3132508A1 (en) 2020-10-01
ZA202106629B (en) 2022-07-27
KR20210146370A (ko) 2021-12-03
US20220144852A1 (en) 2022-05-12
PE20220169A1 (es) 2022-01-28
MX2021011686A (es) 2021-10-22
JP7530380B2 (ja) 2024-08-07
WO2020194160A1 (en) 2020-10-01
CL2021002480A1 (es) 2022-04-29
JP2022527306A (ja) 2022-06-01
EP3946610A1 (en) 2022-02-09
MA55517A (fr) 2022-02-09
CO2021012559A2 (es) 2021-09-30
BR112021018947A2 (pt) 2022-02-08
AU2020245263A1 (en) 2021-10-07
CN113631228B (zh) 2023-10-13
SG11202109191SA (en) 2021-09-29
ECSP21071644A (es) 2021-12-30
CN113631228A (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
MX2021011686A (es) Compuestos macrociclicos como agonistas de sting.
MX2023001311A (es) Agonistas heterociclicos de glp-1.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CR20220029A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CR20220371A (es) Agonistas heterocíclicos de glp-1
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
CR20220251A (es) Nuevos derivados de metilquinazolinona
PH12016501440A1 (en) Novel heterocyclic compounds
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MY194116A (en) Pharmaceutical compounds
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2021007247A (es) Derivados de rapamicina.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2019011182A (es) Combinacion de derivados de isoindolinona con sgi-110.
MX2021014458A (es) Compuestos triciclicos.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.